Kensey Nash originally developed Angio-Seal, and St. Jude bought the marketing and manufacturing rights for the device from Tyco International in early 1999. "Angio-Seal will now be marketed by one of ...

Recently published results from the Cardiovascular and Interventional Radiological Society of Europe (“CIRSE”) vascular closure device registry further validated the safety and efficacy of medical ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Results from a Cordis analysis presented at the 14 th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress in Madrid indicates ...

Please provide your email address to receive an email when new articles are posted on . Procedures involving use of a collagen plug-based vascular closure device rarely led to the onset of critical ...

CHICAGO, IL–Use of a large-bore vascular closure device tested in patients undergoing transcatheter aortic valve replacement and endovascular aortic repair procedures appears to be safe and effective ...

Co announces regulatory approval from the Ministry of Health, Labor and Welfare, in addition to reimbursement approval, for the angio-seal STS plus Vascular closure device. U.S. President Joe Biden ...

The European Commission has approved the $25 billion merger of Abbott Labs and St. Jude Medical, contingent on Abbott selling two cardiovascular devices. Abbott and St. Jude compete on vessel closure ...

En route to Abbott’s acquisition of St. Jude Medical, the duo is agreeing to sell off portions of their vascular and electrophysiology units, worth about $1.12 billion, to Terumo. The transaction is ...

WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves the risk of access site-related vascular complications during a patient’s’ ...

Prior to the inception of percutaneous arterial closure devices, small-sheath size arterial puncture sites were managed with manual compression, which is labor intensive and requires a health care ...